Who
Charles M. Warden
Director
Company insider
Files Form 4 as: Director and 10% owner, Ocular Therapeutix; 10% owner, Phaserx; 10% owner, Inogen.
In numbers
- Trades disclosed
- 54
- Buys
- 1
- Sells
- 6
- Bought
- $3.0M
- Sold
- $17.1M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 30 Jul 2014
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 24 Jul 2024filed 26 Jul 2024 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 24 Jul 2024filed 26 Jul 2024 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 16 Jun 2022filed 21 Jun 2022 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,800 at $0.00 | filing |
| 16 Jun 2022filed 21 Jun 2022 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code A | —8,933 at $0.00 | filing |
| 18 Jun 2021filed 22 Jun 2021 | OCUL Ocular Therapeutixoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 15 Feb 2021filed 17 Feb 2021 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code J | —1,456,780 at $0.00 | filing |
| 15 Feb 2021filed 17 Feb 2021 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code J | —375,121 at $0.00 | filing |
| 15 Feb 2021filed 17 Feb 2021 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code J | —375,121 at $0.00 | filing |
| 15 Feb 2021filed 17 Feb 2021 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code J | —35,912 at $0.00 | filing |
| 15 Feb 2021filed 17 Feb 2021 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code J | —8,604 at $0.00 | filing |
| 4 Dec 2020filed 8 Dec 2020 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code J | —745,597 at $0.00 | filing |
| 4 Dec 2020filed 8 Dec 2020 | OCUL Ocular TherapeutixBiotechnology | SEC FORM 4 Code J | —37,208 at $0.00 | filing |
News
Inogen (NASDAQ:INGN) vs. Accuray (NASDAQ:ARAY) Critical AnalysisINGN · tickerreport.com · 22 Oct 2026Ocular Therapeutix (NASDAQ:OCUL) Stock: Insider Todd Anderman Sells 11,984 SharesOCUL · themarketsdaily.com · 15 Oct 2026Ocular Therapeutix (NASDAQ:OCUL) Upgraded to Strong-Buy at UBS GroupOCUL · dailypolitical.com · 14 Oct 2026Contrasting Ocular Therapeutix (NASDAQ:OCUL) and Bausch Health Cos (NYSE:BHC)OCUL · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Charles M. Warden; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.